Deutsche Bank analyst Emmanuel Papadakis upgraded Roche (RHHBY) to Hold from Sell with an unchanged price target of CHF 215. The company announced “sufficiently interesting data” for its weekly injectable CT-388 which provide the prospect of credible competition to Novo Nordisk (NVO) and Eli Lilly (LLY) in the mid- and long-term, the analyst tells investors in a research note. The firm upgraded the shares after adding the obesity asset into its model.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
- Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- Novo Nordisk mim8 data near Jefferies’ ‘best’ case scenario
- FTC expands patent listing challenges for drugs
- Roche price target lowered to CHF 238 from CHF 248 at UBS